Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.

Research output: Contribution to journalArticle

Standard

Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. / Vos, Stephanie J B; Verhey, Frans; Frölich, Lutz; Kornhuber, Johannes; Wiltfang, Jens; Maier, Wolfgang; Peters, Oliver; Rüther, Eckart; Nobili, Flavio; Morbelli, Silvia; Frisoni, Giovanni B; Drzezga, Alexander; Didic, Mira; van Berckel, Bart N M; Simmons, Andrew; Soininen, Hilkka; Kłoszewska, Iwona; Mecocci, Patrizia; Tsolaki, Magda; Vellas, Bruno; Lovestone, Simon; Muscio, Cristina; Herukka, Sanna-Kaisa; Salmon, Eric; Bastin, Christine; Wallin, Anders; Nordlund, Arto; de Mendonça, Alexandre; Silva, Dina; Santana, Isabel; Lemos, Raquel; Engelborghs, Sebastiaan; Van der Mussele, Stefan; Freund-Levi, Yvonne; Wallin, Åsa; Hampel, Harald; van der Flier, Wiesje; Scheltens, Philip; Visser, Pieter Jelle.

In: Brain, Vol. 138, No. Feb 17, 2015, p. 1327-1338.

Research output: Contribution to journalArticle

Harvard

Vos, SJB, Verhey, F, Frölich, L, Kornhuber, J, Wiltfang, J, Maier, W, Peters, O, Rüther, E, Nobili, F, Morbelli, S, Frisoni, GB, Drzezga, A, Didic, M, van Berckel, BNM, Simmons, A, Soininen, H, Kłoszewska, I, Mecocci, P, Tsolaki, M, Vellas, B, Lovestone, S, Muscio, C, Herukka, S-K, Salmon, E, Bastin, C, Wallin, A, Nordlund, A, de Mendonça, A, Silva, D, Santana, I, Lemos, R, Engelborghs, S, Van der Mussele, S, Freund-Levi, Y, Wallin, Å, Hampel, H, van der Flier, W, Scheltens, P & Visser, PJ 2015, 'Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.', Brain, vol. 138, no. Feb 17, pp. 1327-1338. https://doi.org/10.1093/brain/awv029

APA

Vos, S. J. B., Verhey, F., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., ... Visser, P. J. (2015). Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 138(Feb 17), 1327-1338. https://doi.org/10.1093/brain/awv029

CBE

Vos SJB, Verhey F, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Morbelli S, Frisoni GB, Drzezga A, Didic M, van Berckel BNM, Simmons A, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Muscio C, Herukka S-K, Salmon E, Bastin C, Wallin A, Nordlund A, de Mendonça A, Silva D, Santana I, Lemos R, Engelborghs S, Van der Mussele S, Freund-Levi Y, Wallin Å, Hampel H, van der Flier W, Scheltens P, Visser PJ. 2015. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. 138(Feb 17):1327-1338. https://doi.org/10.1093/brain/awv029

MLA

Vancouver

Vos SJB, Verhey F, Frölich L, Kornhuber J, Wiltfang J, Maier W et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. 2015;138(Feb 17):1327-1338. https://doi.org/10.1093/brain/awv029

Author

Vos, Stephanie J B ; Verhey, Frans ; Frölich, Lutz ; Kornhuber, Johannes ; Wiltfang, Jens ; Maier, Wolfgang ; Peters, Oliver ; Rüther, Eckart ; Nobili, Flavio ; Morbelli, Silvia ; Frisoni, Giovanni B ; Drzezga, Alexander ; Didic, Mira ; van Berckel, Bart N M ; Simmons, Andrew ; Soininen, Hilkka ; Kłoszewska, Iwona ; Mecocci, Patrizia ; Tsolaki, Magda ; Vellas, Bruno ; Lovestone, Simon ; Muscio, Cristina ; Herukka, Sanna-Kaisa ; Salmon, Eric ; Bastin, Christine ; Wallin, Anders ; Nordlund, Arto ; de Mendonça, Alexandre ; Silva, Dina ; Santana, Isabel ; Lemos, Raquel ; Engelborghs, Sebastiaan ; Van der Mussele, Stefan ; Freund-Levi, Yvonne ; Wallin, Åsa ; Hampel, Harald ; van der Flier, Wiesje ; Scheltens, Philip ; Visser, Pieter Jelle. / Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. In: Brain. 2015 ; Vol. 138, No. Feb 17. pp. 1327-1338.

RIS

TY - JOUR

T1 - Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.

AU - Vos, Stephanie J B

AU - Verhey, Frans

AU - Frölich, Lutz

AU - Kornhuber, Johannes

AU - Wiltfang, Jens

AU - Maier, Wolfgang

AU - Peters, Oliver

AU - Rüther, Eckart

AU - Nobili, Flavio

AU - Morbelli, Silvia

AU - Frisoni, Giovanni B

AU - Drzezga, Alexander

AU - Didic, Mira

AU - van Berckel, Bart N M

AU - Simmons, Andrew

AU - Soininen, Hilkka

AU - Kłoszewska, Iwona

AU - Mecocci, Patrizia

AU - Tsolaki, Magda

AU - Vellas, Bruno

AU - Lovestone, Simon

AU - Muscio, Cristina

AU - Herukka, Sanna-Kaisa

AU - Salmon, Eric

AU - Bastin, Christine

AU - Wallin, Anders

AU - Nordlund, Arto

AU - de Mendonça, Alexandre

AU - Silva, Dina

AU - Santana, Isabel

AU - Lemos, Raquel

AU - Engelborghs, Sebastiaan

AU - Van der Mussele, Stefan

AU - Freund-Levi, Yvonne

AU - Wallin, Åsa

AU - Hampel, Harald

AU - van der Flier, Wiesje

AU - Scheltens, Philip

AU - Visser, Pieter Jelle

PY - 2015

Y1 - 2015

N2 - Three sets of research criteria are available for diagnosis of Alzheimer's disease in subjects with mild cognitive impairment: the International Working Group-1, International Working Group-2, and National Institute of Aging-Alzheimer Association criteria. We compared the prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage according to these criteria. Subjects with mild cognitive impairment (n = 1607), 766 of whom had both amyloid and neuronal injury markers, were recruited from 13 cohorts. We used cognitive test performance and available biomarkers to classify subjects as prodromal Alzheimer's disease according to International Working Group-1 and International Working Group-2 criteria and in the high Alzheimer's disease likelihood group, conflicting biomarker groups (isolated amyloid pathology or suspected non-Alzheimer pathophysiology), and low Alzheimer's disease likelihood group according to the National Institute of Ageing-Alzheimer Association criteria. Outcome measures were the proportion of subjects with Alzheimer's disease at the mild cognitive impairment stage and progression to Alzheimer's disease-type dementia. We performed survival analyses using Cox proportional hazards models. According to the International Working Group-1 criteria, 850 (53%) subjects had prodromal Alzheimer's disease. Their 3-year progression rate to Alzheimer's disease-type dementia was 50% compared to 21% for subjects without prodromal Alzheimer's disease. According to the International Working Group-2 criteria, 308 (40%) subjects had prodromal Alzheimer's disease. Their 3-year progression rate to Alzheimer's disease-type dementia was 61% compared to 22% for subjects without prodromal Alzheimer's disease. According to the National Institute of Ageing-Alzheimer Association criteria, 353 (46%) subjects were in the high Alzheimer's disease likelihood group, 49 (6%) in the isolated amyloid pathology group, 220 (29%) in the suspected non-Alzheimer pathophysiology group, and 144 (19%) in the low Alzheimer's disease likelihood group. The 3-year progression rate to Alzheimer's disease-type dementia was 59% in the high Alzheimer's disease likelihood group, 22% in the isolated amyloid pathology group, 24% in the suspected non-Alzheimer pathophysiology group, and 5% in the low Alzheimer's disease likelihood group. Our findings support the use of the proposed research criteria to identify Alzheimer's disease at the mild cognitive impairment stage. In clinical settings, the use of both amyloid and neuronal injury markers as proposed by the National Institute of Ageing-Alzheimer Association criteria offers the most accurate prognosis. For clinical trials, selection of subjects in the National Institute of Ageing-Alzheimer Association high Alzheimer's disease likelihood group or the International Working Group-2 prodromal Alzheimer's disease group could be considered.

AB - Three sets of research criteria are available for diagnosis of Alzheimer's disease in subjects with mild cognitive impairment: the International Working Group-1, International Working Group-2, and National Institute of Aging-Alzheimer Association criteria. We compared the prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage according to these criteria. Subjects with mild cognitive impairment (n = 1607), 766 of whom had both amyloid and neuronal injury markers, were recruited from 13 cohorts. We used cognitive test performance and available biomarkers to classify subjects as prodromal Alzheimer's disease according to International Working Group-1 and International Working Group-2 criteria and in the high Alzheimer's disease likelihood group, conflicting biomarker groups (isolated amyloid pathology or suspected non-Alzheimer pathophysiology), and low Alzheimer's disease likelihood group according to the National Institute of Ageing-Alzheimer Association criteria. Outcome measures were the proportion of subjects with Alzheimer's disease at the mild cognitive impairment stage and progression to Alzheimer's disease-type dementia. We performed survival analyses using Cox proportional hazards models. According to the International Working Group-1 criteria, 850 (53%) subjects had prodromal Alzheimer's disease. Their 3-year progression rate to Alzheimer's disease-type dementia was 50% compared to 21% for subjects without prodromal Alzheimer's disease. According to the International Working Group-2 criteria, 308 (40%) subjects had prodromal Alzheimer's disease. Their 3-year progression rate to Alzheimer's disease-type dementia was 61% compared to 22% for subjects without prodromal Alzheimer's disease. According to the National Institute of Ageing-Alzheimer Association criteria, 353 (46%) subjects were in the high Alzheimer's disease likelihood group, 49 (6%) in the isolated amyloid pathology group, 220 (29%) in the suspected non-Alzheimer pathophysiology group, and 144 (19%) in the low Alzheimer's disease likelihood group. The 3-year progression rate to Alzheimer's disease-type dementia was 59% in the high Alzheimer's disease likelihood group, 22% in the isolated amyloid pathology group, 24% in the suspected non-Alzheimer pathophysiology group, and 5% in the low Alzheimer's disease likelihood group. Our findings support the use of the proposed research criteria to identify Alzheimer's disease at the mild cognitive impairment stage. In clinical settings, the use of both amyloid and neuronal injury markers as proposed by the National Institute of Ageing-Alzheimer Association criteria offers the most accurate prognosis. For clinical trials, selection of subjects in the National Institute of Ageing-Alzheimer Association high Alzheimer's disease likelihood group or the International Working Group-2 prodromal Alzheimer's disease group could be considered.

U2 - 10.1093/brain/awv029

DO - 10.1093/brain/awv029

M3 - Article

VL - 138

SP - 1327

EP - 1338

JO - Brain

JF - Brain

SN - 1460-2156

IS - Feb 17

ER -